---
schema_version: "secwatch.filing_event.v1"
accession: "0001714899-23-000131"
form_type: "8-K"
ticker: "DNLI"
cik: "0001714899"
company_name: "Denali Therapeutics Inc."
filed_at: "2023-08-21T23:59:59+00:00"
generated_at: "2026-06-11T06:20:07.498116+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Denali amends Biogen pacts; milestones unchanged, Biogen waives option rights

## Summary
- Amendment to LRRK2 Collaboration and ROFN agreements executed Aug 17, 2023.
- Milestone schedule revised but total eligible milestone value remains unchanged.
- Biogen waives option to second program and rights of first negotiation for two TV-enabled programs.
- Relates to prior announcements on June 5, 2023 (LRRK2) and April 12, 2023 (ATV:Aβ).
- Other terms of original agreements remain in full force per Denali.

## SEC filing metadata
- accession: 0001714899-23-000131
- form_type: 8-K
- ticker: DNLI
- cik: 0001714899
- company_name: Denali Therapeutics Inc.
- filed_at: 2023-08-21T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 1.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1714899/000171489923000131/0001714899-23-000131-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1714899/000171489923000131/dnli-20230817.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001714899-23-000131
- JSON: https://secwatch.observer/filing/0001714899-23-000131.json
- Plain text: https://secwatch.observer/filing/0001714899-23-000131.txt

## Key facts
- Material Agreements
  Denali Therapeutics Inc. amended Amendment with Biogen MA, Inc. and Biogen International GmbH (effective 2023-08-17).
  - Action: amendment
  - Agreement: license
  - Counterparty: Biogen MA, Inc. and Biogen International GmbH
  - Effective: 2023-08-17
  source text: on August 17, 2023, Denali Therapeutics Inc., (“Denali” or “we”) and Biogen MA, Inc. and Biogen International GmbH, (collectively, “Biogen”) executed an Amendment to the Definitive LRRK2 Agreement and Waiver of and Amendment to Right of First Negotiation, Option, and License Agreement (the “Amendment”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1714899/000171489923000131/0001714899-23-000131-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.